ChemoCentryx Inc said on Friday the US health agency approved its lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company's shares up by more than 70%. US health agency approved avacopan, which will be available under brand name Tavneos in the next few weeks, will have a wholesale price of between $150,000 and $200,000 per patient …
